- Home
- INVA
INVA
Innoviva Inc.
as 04-23-2025 4:00pm EST
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | BURLINGAME |
| Market Cap: | N/A | IPO Year: | 2004 |
| Target Price: | $55.00 | AVG Volume (30 days): | 887.6K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.36 | EPS Growth: | -83.56 |
| 52 Week Low/High: | $14.89 - $21.28 | Next Earning Date: | 05-07-2025 |
| Revenue: | $358,711,000 | Revenue Growth: | 15.54% |
| Revenue Growth (this year): | 0.08% | Revenue Growth (next year): | 10.19% |
Stock Insider Trading Activity of Innoviva Inc. (INVA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DENNER ALEXANDER J | INVA | 10% Owner | Mar 4 '25 | Sell | $17.59 | 1,618,295 | $28,395,442.43 | 7,125,825 |
Latest Innoviva Inc. News
INVA Breaking Stock News: Dive into INVA Ticker-Specific Updates for Smart Investing
Argus Research
8 days ago
INVA: Raising target price to $19.00
Simply Wall St.
14 days ago
Are Innoviva, Inc.'s (NASDAQ:INVA) Mixed Financials Driving The Negative Sentiment?
Argus Research
15 days ago
INVA: Lowering target price to $18.00
Argus Research
22 days ago
INVA: Raising target price to $19.00
Argus Research
a month ago
INVA: What does Argus have to say about INVA?
Barrons.com
a month ago
Victoria’s Secret, Bitdeer, and More Stocks See Activist Action
Barrons.com
a month ago
WEX, Lamb Weston, and More Stocks See Action From Activist Investors
MT Newswires
a month ago
Armata Pharmaceuticals Enters $10 Million Secured Credit Agreement with Innoviva
Compare INVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INVA Innoviva Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.